Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1373859 | Bioorganic & Medicinal Chemistry Letters | 2006 | 6 Pages |
Abstract
A series of new derivatives of the clinically used aminoglycoside antibiotic paromomycin were designed, synthesized, and their ability to read-through premature stop codon mutations was examined in both in vitro translation system and ex vivo mammalian cultured cells. One of these structures, a pseudo-trisaccharide derivative, showed notably higher stop codon read-through activity in cultured cells compared to those of paromomycin and gentamicin.
Graphical abstractA series of new derivatives of paromomycin was designed, synthesized, and evaluated for read-through activity of premature stop codon mutations. Compound 3 showed excellent activity in cultured mammalian cells.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Igor Nudelman, Annie Rebibo-Sabbah, Dalia Shallom-Shezifi, Mariana Hainrichson, Ido Stahl, Tamar Ben-Yosef, Timor Baasov,